Expert Answers to Common Questions for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma: Considerations for Community Practice

Summary: Guest: Caron A. Jacobson, MD <br> <p>CD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR T-cell therapies have historically been given in the inpatient setting, interest in outpatient delivery is growing, and this option may become more feasible if logistical issues and lack of multidisciplinary collaboration between the community provider and the CAR-T cell therapy center can be overcome. <span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p> <p><span xml:lang="EN-US" data-contrast="auto">AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on</span><span xml:lang="EN-US" data-contrast="none"> CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies.</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>